Advanced Medical Solutions Group (AMS) H2 2024 earnings summary

Executive summary

• Group revenue grew 43% year-over-year, driven by strong Surgical performance and acquisitions.

• Transformative acquisitions of Peters Surgical and Syntacoll significantly expanded capabilities and market reach.

• New US LiquiBand® route to market strategy delivered robust growth throughout 2024.

• Integration of acquired businesses progressing well, supporting long-term growth.

Financial highlights

• Revenue increased 43% at reported currency to £177.5 million compared to 2023.

• Adjusted EBITDA rose 35% to £40.2 million year-over-year.

• Adjusted pre-tax profit up 14% to £29.4 million.

• Net debt at year-end was £55.8 million, compared to net cash of £60.2 million in 2023, reflecting acquisition activity.

• Proposed 10% increase in full-year dividend to 2.60p per share.

Outlook and guidance

• FY 2025 outlook unchanged, with revenue and EBITDA expected in line with Board expectations.

• 2025 has started well, with good business performance and positive momentum.

• Group positioned for strong, long-term growth.